{"id":"W2092228974","doi":"10.1038/bjc.2014.244","title":"Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial","year":2014,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"Genentech; Eisai; GlaxoSmithKline; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Axitinib; Sorafenib; Medicine; Sunitinib; Internal medicine; Oncology; Renal cell carcinoma; Urology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005084442,0.002060363,0.004137483,0.000339362,0.0003972898,0.001395392,0.0006811406,0.0009469214,0.007257114],"category_scores_gemma":[0.004442644,0.0006895823,0.00663682,0.00057513,0.0007911107,0.0008717356,0.0006553049,0.002603529,0.0007125319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001100457,"about_ca_system_score_gemma":0.00145645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001146774,"about_ca_topic_score_gemma":0.003835117,"domain_scores_codex":[0.9975982,0.001565026,0.0001949982,0.0002651199,0.0001536504,0.000222995],"domain_scores_gemma":[0.9972931,0.00100547,0.0007412251,0.0002970806,0.0001793313,0.00048383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9815724,0.0006622865,0.00117022,0.0008418896,0.007306892,0.00002458341,0.00003163733,0.0003076517,0.0009600282,0.00004268525,0.0005680798,0.006511779],"study_design_scores_gemma":[0.9627522,0.02233776,0.00609211,0.00007628352,0.00681425,0.00005348361,0.00002249344,0.0003781242,0.0002984807,0.0002284336,0.0009281066,0.00001821275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9554647,0.03269367,0.001658736,0.0008690656,0.0009962654,0.003202219,0.002328621,0.0001331309,0.002653695],"genre_scores_gemma":[0.9802825,0.008409685,0.001059763,0.0008321861,0.0006663218,0.003710354,0.002357196,0.00005249566,0.002629402],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007257114,"threshold_uncertainty_score":0.02688938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02554856447617362,"score_gpt":0.3147698027311995,"score_spread":0.2892212382550259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}